adenoassoci
viru
aav
one
promis
viral
gene
transfer
vector
shown
effect
longterm
gene
express
diseas
correct
low
toxic
anim
model
well
toler
human
clinic
trial
surfac
aav
capsid
essenti
compon
involv
cell
bind
intern
traffick
within
target
cell
prior
develop
gene
therapi
strategi
util
aav
serotyp
care
consid
sinc
capsid
exhibit
uniqu
tissu
tropism
transduct
effici
sever
approach
undertaken
effort
target
aav
vector
specif
cell
type
includ
util
natur
serotyp
target
desir
cellular
receptor
produc
pseudotyp
vector
engin
chimer
mosaic
aav
capsid
capsid
modif
incorpor
vector
product
purif
method
provid
abil
scaleup
manufactur
process
support
human
clinic
trial
protocol
smallscal
largescal
product
aav
well
assay
character
final
vector
product
present
structur
solv
xray
crystallographi
cryoelectron
microscopi
cryoem
provid
basi
ration
vector
design
develop
custom
capsid
specif
target
aav
vector
capsid
aav
shown
remark
stabl
desir
characterist
gene
therapi
vector
howev
recent
shown
aav
serotyp
exhibit
differenti
suscept
proteas
capsid
fragment
pattern
expos
variou
proteas
well
suscept
serotyp
seri
proteas
provid
uniqu
fingerprint
serotyp
use
capsid
ident
valid
addit
serotyp
identif
proteas
suscept
also
util
studi
dynam
structur
chang
must
occur
aav
capsid
perform
variou
function
viru
life
cycl
use
proteas
structur
studi
solut
complement
crystal
structur
studi
viru
gener
protocol
base
proteolysi
aav
serotyp
identif
provid
adenoassoci
viru
aav
singlestrand
dna
viru
current
util
gene
therapi
applic
aav
member
famili
parvovirida
genu
dependoviru
sever
featur
aav
make
promis
candid
gene
transfer
vector
follow
good
safeti
profil
member
genu
associ
diseas
human
viru
replicationdefici
except
special
circumst
replic
spread
aav
well
toler
human
clinic
trial
stabl
longterm
express
transgen
aav
success
use
express
transgen
sever
tissu
includ
brain
muscl
liver
lung
vascular
endothelium
hematopoiet
cell
abil
transduc
divid
nondivid
cell
episom
mainten
wildtyp
aav
exhibit
sitespecif
integr
genom
chromosom
howev
major
vector
genom
appear
maintain
episom
therefor
risk
integr
minim
compar
retrovir
vector
requir
integr
host
genom
potenti
activ
protooncogen
low
immunogen
unlik
adenovir
vector
robust
cell
respons
vector
gener
aav
although
humor
immun
respons
gener
may
result
viral
neutral
use
aav
serotyp
may
circumv
respons
allow
repeat
treatment
altern
immunosuppress
therapi
may
use
treatment
aav
avoid
immun
respons
physiochem
stabil
aav
virion
highli
stabl
wide
rang
ph
temperatur
featur
import
product
purif
method
clinicalgrad
aav
vector
well
stabil
final
vector
product
genom
aav
base
linear
singlestrand
dna
two
gene
rep
cap
flank
invert
termin
repeat
itr
itr
consist
nucleotid
form
characterist
tshape
hairpin
sequenc
requir
ci
viral
dna
replic
packag
rep
gene
encod
four
nonstructur
protein
play
role
viral
genom
replic
transcript
well
packag
translat
mrna
transcrib
promot
rep
deriv
mrna
transcrib
promot
altern
splice
replac
amino
acid
ctermin
element
amino
acid
element
cap
gene
encod
three
structur
protein
aav
capsid
kda
kda
kda
translat
mrna
transcrib
promot
differenti
splice
yield
major
minor
splice
product
translat
minor
splice
mrna
yield
less
protein
translat
abund
major
splice
mrna
howev
translat
less
effici
initi
acg
codon
translat
effici
favor
kozak
context
result
aav
capsid
protein
differ
ntermin
region
present
matur
virion
ratio
singlestrand
dna
genom
aav
product
depict
fig
work
myer
carter
provid
evid
structur
protein
aav
assembl
empti
capsid
genom
packag
preform
capsid
pulsechas
experi
show
empti
particl
rapidli
accumul
min
matur
full
virion
accumul
slowli
h
also
show
number
empti
viral
particl
decreas
rate
number
dnacontain
matur
virion
increas
cours
infect
addit
de
la
maza
carter
show
di
particl
particl
delet
aav
genom
packag
appar
normal
capsid
indic
fulllength
viral
genom
dna
requir
assembl
structur
integr
aav
capsid
absenc
capsid
assembl
ssdna
accumul
suggest
empti
capsid
form
first
interact
preform
aav
capsid
provid
mechan
nonstructur
protein
helicas
activ
insert
viral
dna
within
cell
capsid
assembl
occur
center
within
nucleu
coloc
rep
protein
capsid
protein
dna
empti
aav
capsid
produc
express
aav
cap
gene
insect
cell
use
baculoviru
express
system
mammalian
cell
util
recombin
adenoviru
express
aav
capsid
protein
system
advanc
structur
studi
aav
capsid
result
larg
amount
empti
capsid
viruslik
particl
vlp
produc
studi
aav
assembl
demonstr
alon
suffici
form
vlp
requir
infect
subsequ
shown
uniqu
nterminu
phospholipas
activ
contain
nuclear
local
signal
nl
nterminu
also
nl
may
play
role
transport
nucleu
howev
shown
nterminu
nonessenti
infecti
viru
produc
lack
entir
addit
nterminu
replac
green
fluoresc
protein
capsid
still
assembl
maintain
infect
demonstr
toler
peptid
insert
may
use
incorpor
peptid
capsid
cellspecif
target
aav
adenoassoci
viru
capsid
nm
diamet
compos
subunit
arrang
icosahedr
symmetri
aav
number
featur
make
attract
gene
transfer
vector
mani
studi
focus
basic
biolog
viru
includ
studi
address
structur
characterist
cryoem
crystal
structur
determin
crystal
structur
current
progress
dependovirus
share
subunit
fold
member
famili
parvovirida
includ
insect
densovirus
autonom
replic
parvovirus
canin
parvoviru
cpv
minut
viru
mice
mvm
even
though
aav
share
low
capsid
primari
sequenc
ident
monomer
subunit
aav
conserv
core
common
viral
capsid
protein
figur
depict
structur
monomer
subunit
determin
xie
et
al
motif
eightstrand
antiparallel
motif
jellyrol
strand
label
bi
label
present
parvovirus
includ
aav
surprisingli
genet
capsid
mutant
conserv
core
mutat
mutat
mutat
mutat
unabl
assembl
capsid
aav
long
loop
insert
strand
core
label
accord
strand
flank
long
interstrand
loop
contain
ribbon
element
secondari
structur
form
much
outer
surfac
featur
aav
capsid
gh
loop
longest
interstrand
loop
three
vp
interact
extens
threefold
axi
symmetri
form
promin
spike
five
de
loop
form
antiparallel
ribbon
fivefold
axi
symmetri
result
cylindr
structur
surround
canyonlik
depress
twofold
axi
symmetri
small
depress
often
refer
twofold
dimpl
analysi
newli
discov
aav
genotyp
identifi
total
hypervari
region
aav
capsid
overlay
region
onto
xray
crystallograph
model
show
region
expos
capsid
surfac
variabl
locat
g
h
strand
implic
format
valley
peak
protrud
threefold
axi
symmetri
surfac
featur
viru
respons
interact
capsid
cellular
receptor
well
antibodi
motif
capsid
surfac
critic
attach
host
cell
first
step
requir
infect
differ
serotyp
aav
util
uniqu
cellular
receptor
primari
receptor
heparin
sulfat
proteoglycan
hspg
bind
cell
surfac
util
secondari
receptor
integrin
human
fibroblast
growth
factor
hepatocyt
growth
factor
cmet
mediat
entri
recent
demonstr
util
altern
coreceptor
cell
lack
integrin
integrin
recognit
sequenc
ngr
amino
acid
within
assembl
capsid
locat
threefold
axi
symmetri
structur
monomer
subunit
determin
xie
et
al
imag
produc
use
coordin
protein
databank
pdb
access
molecular
model
softwar
pymol
wwwpymolorg
provid
delano
scientif
palo
alto
ca
adjac
previous
implic
heparin
bind
ngr
motif
conserv
among
aav
serotyp
except
similar
also
report
bind
heparin
heparan
sulfat
well
receptor
shown
pdgfr
bind
sialic
acid
bind
sialic
acid
util
sialic
acid
well
sialic
acid
howev
unlik
unabl
util
olink
sialic
acid
domain
surfac
aav
capsid
interact
cellular
receptor
found
specif
cell
result
rang
tissu
tropism
seen
variou
aav
serotyp
known
serotyp
aav
differ
cellular
target
antigen
properti
recent
genom
variant
primari
aav
serotyp
discov
new
variant
may
provid
expand
tropism
uniqu
cellular
target
aavmedi
gene
deliveri
util
natur
differ
tropism
aav
serotyp
provid
one
strategi
effici
deliv
aav
vector
specif
target
tissu
select
appropri
capsid
serotyp
target
tissu
import
consider
raav
genom
packag
capsid
serotyp
isotyp
altern
raav
genom
crosspackag
capsid
deriv
anoth
serotyp
process
call
pseudotyp
pseudotyp
vector
capsid
gene
serotyp
clone
rep
transgen
flank
itr
result
vector
capsid
serotyp
packag
transgen
flank
itr
provid
method
compar
transduct
effici
variou
serotyp
abil
choos
effici
one
specif
applic
tabl
list
sever
target
tissu
compar
transduct
effici
select
aav
serotyp
studi
anim
model
effici
transduct
could
involv
cell
entri
associ
receptor
bind
intern
postentri
event
cellular
process
pathway
intracellular
transport
nuclear
entri
process
virion
vector
genom
thoma
et
al
show
vector
uncoat
faster
result
transgen
express
seen
sooner
repeat
vector
deliveri
might
need
order
increas
transgen
express
deliv
two
gene
coordin
fashion
applic
transgen
packag
capsid
differ
aav
serotyp
readministr
circumv
antibodi
neutral
respons
differ
amino
acid
composit
viral
capsid
present
uniqu
epitop
host
immun
system
studi
vector
pancrea
kidney
transduc
tubular
epithelium
glomerular
blood
vessel
interstiti
cell
lung
retina
photoreceptor
cell
hematopoiet
stem
cell
dendrit
cell
continu
cochlear
inner
ear
cell
solid
tumor
melanoma
glioblastoma
glioma
cell
brain
transduc
par
reticul
transduc
entir
midbrain
transduc
pyramid
cell
layer
transduc
dentat
gyru
transduc
neuron
transduc
neuron
glial
cell
transduc
ependym
cell
transduc
glial
cell
ependym
cell
cardiac
tissu
elicit
cytotox
tlymphocyt
ctl
respons
mice
capsid
amino
acid
elicit
respons
wherea
respons
elicit
amino
acid
magnitud
immun
respons
depend
sever
factor
includ
vector
dose
well
rout
site
administr
antibodi
form
transduct
one
aav
serotyp
like
show
weak
interact
serotyp
may
crossreact
anim
transduc
transduc
deliveri
transgen
hamper
howev
anim
transduc
retransduc
develop
neutral
antibodi
respons
region
capsid
shown
respons
gener
cell
respons
rxxr
motif
involv
heparin
bind
region
identifi
involv
uptak
dendrit
cell
well
activ
capsidspecif
cell
altern
serotyp
may
also
provid
treat
cell
heretofor
refractori
aav
infect
stem
cell
demonstr
effici
transduc
hematopoiet
stem
cell
suboptim
level
express
cell
surfac
receptor
viral
vector
hspg
impair
cellular
traffick
vector
ineffici
vector
uncoat
lack
viral
secondstrand
dna
synthesi
howev
abl
transduc
hemotopoiet
stemprogenitor
cell
evalu
shortterm
coloni
assay
well
longterm
bone
marrow
transplant
assay
vivo
also
low
transduct
effici
airway
epithelium
lung
due
low
abund
hspg
apic
surfac
howev
sialic
acid
abund
sugar
apic
surfac
airway
epithelium
pseudotyp
vector
shown
effici
gene
transfer
murin
airway
epithelia
vivo
encapsid
vector
achiev
transduct
rate
suffici
treat
lung
diseas
cystic
fibrosi
cf
recent
determin
transduct
effici
vivo
treatment
pancreat
colon
carcinoma
insuffici
howev
aav
serotyp
yet
test
may
result
better
transduct
target
tissu
bind
differ
cellular
receptor
result
better
transduct
muscl
tissu
sinc
vector
studi
contain
ci
element
aav
capsid
respons
differ
transduct
effici
serotyp
hauck
xiao
produc
seri
capsid
mutant
investig
major
region
capsid
respons
increas
transduct
effici
muscl
tissu
major
tissu
tropism
determin
locat
surfac
region
amino
acid
similar
function
studi
aav
capsid
provid
better
understand
surfac
featur
specif
requir
engin
aav
capsid
effici
target
specif
cell
receptor
like
hspg
present
varieti
cell
type
pose
difficulti
target
vector
specif
tissu
one
approach
limit
gene
express
target
tissu
util
viral
vector
harbor
tissuespecif
promot
genet
modif
aav
capsid
also
provid
altern
approach
retarget
region
capsid
identifi
accept
insert
heterolog
peptid
retarget
girod
et
al
first
demonstr
insert
amino
acid
integrin
bind
peptid
amino
acid
allow
retarget
obtain
genet
map
capsid
wu
et
al
construct
alanin
scan
mutant
differ
posit
aav
capsid
gene
sitedirect
mutagenesi
studi
mutant
show
capsid
toler
modif
still
maintain
infect
amino
acid
igg
bind
domain
insert
capsid
amino
acid
coupl
antibodi
integrin
ckit
receptor
mediat
target
raav
vector
specif
cell
surfac
receptor
endotheli
cell
bind
peptid
identifi
use
phage
display
insert
capsid
amino
acid
transduc
venou
endotheli
cell
significantli
reduc
hepatocyt
transduct
recent
demonstr
could
retarget
heart
util
capsid
mutat
amino
acid
elimin
heparin
bind
requir
infect
liver
perabo
et
al
also
demonstr
insert
amino
acid
peptid
confer
net
neg
charg
ablat
bind
hspg
correl
liver
spleen
detarget
insert
peptid
either
caus
spatial
separ
steric
block
heparin
bind
use
bulki
amino
acid
insert
posit
charg
peptid
reconstitut
abil
bind
hspg
provid
strategi
improv
aav
target
tissu
retarget
aav
tumor
cell
motif
insert
amino
acid
confer
novel
tropism
elimin
heparin
bind
rgd
motif
bind
cellular
integrin
receptor
express
tumor
cell
includ
ovarian
cancer
cell
cell
express
low
level
hspg
nonpermiss
transduct
introduct
peptid
capsid
viabl
strategi
retarget
addit
cell
type
howev
modif
capsid
often
result
reduct
vector
yield
especi
insert
larg
uniqu
ntermin
region
allow
peptid
insert
without
loss
titer
suppli
tran
mosaic
ligand
insert
subset
molecul
result
increas
vector
yield
transduc
titer
compar
virus
carri
insert
capsid
protein
subunit
insert
ha
epitop
ypvdvpdya
amino
acid
result
noninfecti
particl
howev
inclus
wildtyp
capsid
protein
restor
viral
infect
rie
et
al
insert
immunoglobulinbind
fragment
protein
result
least
tenfold
reduct
particl
titer
like
due
larg
size
amino
acid
compar
wildtyp
viru
infecti
titer
order
magnitud
lower
gigout
et
al
gener
mosaic
virus
contain
capsid
protein
rest
capsid
compos
wildtyp
subunit
produc
mosaic
infecti
compar
wildtyp
viru
mosaic
show
tenfold
increas
titer
contain
capsid
protein
averag
subunit
per
capsid
order
magnitud
infecti
mutant
virus
mutat
alanin
abl
elimin
hspg
bind
insert
result
retarget
work
demonstr
first
time
combin
approach
gener
mosaic
alter
tropism
mutat
two
residu
reduc
hspg
bind
could
use
retarget
specif
cell
type
incorpor
motif
amino
acid
enabl
target
integrin
receptor
present
vascular
endotheli
cell
also
possibl
incorpor
small
biotin
acceptor
peptid
bap
posit
purpos
metabol
biotinyl
capsid
purif
use
commerci
avail
avidin
affin
column
mosaic
modif
gener
enabl
retarget
capsid
simplifi
purif
anoth
strategi
broaden
tissu
tropism
gener
aav
mix
chimer
capsid
accomplish
suppli
capsid
gene
two
distinct
aav
serotyp
product
vari
ratio
two
capsid
gene
result
mix
viru
may
exhibit
alter
tropism
rabinowitz
et
al
show
mix
capsid
ratio
result
loss
heparin
bind
abil
virion
transduc
hela
cell
high
level
heparin
sulfat
decreas
abil
transduc
heparinsulfatedefici
cell
line
cho
pgsd
increas
composit
virion
chang
chimera
also
may
show
combin
tropism
serotyp
broaden
tropism
virion
kohlbrenn
et
al
util
chimer
capsid
improv
infect
express
insect
cell
determin
vector
gener
use
baculoviru
system
low
infect
due
insuffici
phospholipas
activ
substitut
entir
protein
chimer
capsid
result
increas
phospholipas
activ
level
enhanc
transduct
gener
chimera
also
provid
method
function
defin
structur
related
newli
discov
serotyp
abil
gener
stabl
chimer
capsid
suggest
subunit
differ
serotyp
structur
compat
convers
mix
ineffici
packag
genom
inabl
gener
stabl
virion
may
reflect
failur
essenti
structur
subunit
interact
one
axe
symmetri
altern
nonstructur
rep
protein
interact
occur
surfac
capsid
packag
may
compat
chimera
suggest
structur
aav
capsid
provid
potent
gene
deliveri
vehicl
shown
great
promis
anim
model
well
human
clinic
trial
conduct
date
aav
vector
develop
multitud
diseas
includ
disord
central
nervou
system
vector
method
treatment
inadequ
exampl
includ
parkinson
diseas
alzheim
diseas
gene
therapi
approach
util
aav
also
address
classic
genet
disord
lysosom
storag
disord
hemophilia
cystic
fibrosi
mani
diseas
amen
aav
gene
therapi
approach
list
tabl
aav
vector
treat
diseas
shown
signific
persist
gene
transfer
without
toxic
human
clinic
trial
vector
administ
effect
intracellular
express
protein
dystrophin
express
secret
therapeut
protein
result
cross
correct
cell
aav
may
also
util
vaccin
deliv
specif
antigen
exampl
target
dendrit
cell
allow
antigen
present
aav
vector
produc
express
compon
papillomaviru
caus
agent
cervic
cancer
well
receptor
spike
protein
sar
coronaviru
aavbas
gene
transfer
therapeut
potenti
arrest
revers
cours
inherit
acquir
diseas
import
consider
develop
suitabl
gene
deliveri
vector
abil
produc
quantiti
vector
requir
treat
human
patient
histor
product
method
limit
develop
aav
vector
improv
product
purif
method
result
better
yield
increas
puriti
higher
titer
develop
scalabl
system
recombin
aav
vector
manufactur
use
twoplasmid
system
shown
fig
one
plasmid
harbor
therapeut
vector
express
adiponectin
rat
gene
flank
itr
one
contain
aav
rep
cap
gene
well
helper
function
replic
adenoviru
helper
function
provid
express
va
rna
helper
plasmid
adenoviru
gene
product
express
cell
util
product
two
plasmid
cotransfect
cell
result
product
aav
virion
contain
therapeut
gene
flank
itr
itr
viral
sequenc
remain
purif
raav
vector
protocol
see
appendix
describ
smallscal
product
purif
raav
vector
describ
zolotukhin
et
al
gener
cell
expand
transfect
harvest
h
posttransfect
cell
lyse
load
onto
either
cesium
chlorid
iodixanol
gradient
separ
infecti
virion
empti
capsid
cellular
protein
viru
purifi
use
either
heparin
affin
chromatographi
ionexchang
chromatographi
chromatographi
method
use
depend
natur
receptor
aav
well
charg
characterist
viral
particl
shown
fig
follow
column
chromatographi
viru
concentr
character
protocol
yield
vector
stock
rel
pure
howev
owe
densiti
gradient
requir
method
easili
scalabl
protocol
describ
largescal
product
purif
raav
vector
describ
snyder
et
al
protocol
provid
method
suitabl
largescal
product
vector
scalabl
product
vector
cgmp
condit
clinic
trial
cell
factori
cell
transfect
incub
h
harvest
cell
pellet
resuspend
lysi
buffer
contain
deoxychol
reduc
viral
particl
aggreg
u
benzonaseml
degrad
cellular
plasmid
nonpackag
nucleic
acid
microfluid
util
lyse
cell
order
form
fine
suspens
load
directli
onto
streamlin
heparin
column
column
wash
viru
elut
column
phosphatebuff
salin
pb
contain
nacl
total
ionic
strength
mm
peak
fraction
streamlin
heparin
column
brought
nacl
load
phenyl
sever
assay
character
final
product
respect
titer
puriti
ident
potenc
particl
infecti
ratio
stabil
list
tabl
addit
vector
product
safeti
test
conduct
prior
anim
human
studi
assay
use
product
character
safeti
test
includ
tabl
determin
titer
infecti
particl
produc
serial
dilut
replic
assay
dra
vector
genom
dotblot
hybrid
determin
genomecontain
vector
concentr
pcr
capsid
elisa
determin
total
capsid
protein
concentr
enabl
determin
empti
particl
prep
bradford
western
electron
microscopi
optic
densiti
od
near
futur
custom
aav
gene
therapi
vector
may
consist
modifi
capsid
allow
specif
target
treat
patient
variou
diseas
structur
aav
capsid
provid
basi
ration
vector
design
howev
structur
avail
autonom
parvovirus
dependovirus
provid
snapshot
capsid
topolog
low
energi
conform
knowledg
aav
viral
capsid
structur
solut
limit
howev
structur
must
dynam
carri
variou
function
requir
viral
attach
entri
well
traffick
within
cell
cryoem
studi
shown
uniqu
nterminu
intern
capsid
base
addit
densiti
twofold
axi
symmetri
vitro
upon
heat
treatment
aav
capsid
shown
region
extern
mutagenesi
experi
shown
extern
occur
pore
fivefold
axi
symmetri
previous
antibodi
produc
detect
variou
region
capsid
protein
antibodi
epitop
ctermin
end
capsid
protein
primarili
intern
twofold
axi
symmetri
assembl
capsid
antibodi
use
detect
denatur
aav
protein
epitop
highli
conserv
among
aav
serotyp
antibodi
recogn
uniqu
ntermin
region
epitop
ntermin
region
polyclon
antibodi
produc
capsid
well
serotyp
addit
antibodi
produc
recogn
conform
epitop
present
assembl
capsid
well
capsid
antibodi
util
serotyp
ident
test
final
vector
product
howev
mani
antibodi
crossreact
multipl
serotyp
histor
aav
shown
remark
stabl
gener
resist
proteas
howev
demonstr
expos
proteas
specif
region
capsid
suscept
proteolysi
owe
differ
primari
sequenc
capsid
protein
differ
serotyp
well
result
differ
capsid
structur
proteolysi
util
aav
serotyp
determin
differ
serotyp
provid
uniqu
fragment
pattern
cleav
proteas
serotyp
rel
resist
other
suscept
trypsin
chymotrypsin
figur
depict
proteas
map
aav
capsid
capsid
serotyp
determin
gener
assay
describ
protocol
proteolysi
use
togeth
specif
antibodi
provid
power
map
techniqu
method
identifi
confirm
serotyp
aav
capsid
kda
kda
kda
kda
kda
kda
kda
b
proteinas
k
trypsin
chymotrypsin
serotyp
fig
proteas
map
aav
capsid
capsid
serotyp
determin
sampl
digest
proteas
case
trypsin
one
set
sampl
chymotrypsin
set
western
blot
perform
use
polyclon
antisera
aav
capsid
base
fragment
pattern
serotyp
determin
made
undigest
sampl
sampl
digest
h
shown
resist
proteas
exhibit
differ
fragment
pattern
sampl
repres
undigest
capsid
protein
b
differ
aav
serotyp
demonstr
differ
suscept
proteas
due
differ
primari
amino
acid
sequenc
differenti
suscept
provid
uniqu
signatur
serotyp
allow
capsid
serotyp
identif
summari
aav
capsid
major
determin
gene
transfer
effici
target
sever
approach
avail
target
aav
viral
vector
specif
cell
type
includ
util
natur
serotyp
target
desir
cellular
receptor
produc
pseudotyp
vector
well
engin
chimer
mosaic
capsid
genet
mutat
aav
capsid
identifi
region
accommod
peptid
insert
modif
specif
target
use
modifi
capsid
may
enhanc
effici
target
specif
make
potent
safe
vector
sever
genet
diseas
amen
treatment
aav
vector
make
aav
valuabl
gene
deliveri
vehicl
especi
disord
current
therapi
inadequ
nonexist
current
product
method
allow
gener
quantiti
viru
need
clinic
trial
purif
method
develop
sever
serotyp
addit
assay
develop
final
product
character
ensur
patient
safeti
seed
plate
cell
confluent
follow
day
h
prior
transfect
cell
cultur
dulbecco
modifi
eagl
medium
dmem
supplement
fetal
bovin
serum
fb
penicillin
streptomycin
check
plate
prior
transfect
ensur
optim
confluenc
chang
media
ensur
cell
volum
ml
care
disrupt
monolay
transfect
prepar
dna
mixtur
room
temperatur
conic
tube
follow
mix
helper
plasmid
raav
vector
plasmid
dna
per
plate
molar
ratio
bring
final
volum
dna
mixtur
ml
steril
dh
add
ml
cacl
dna
cacl
concentr
prepar
ten
conic
tube
ml
hb
transfect
plate
ml
hb
total
transfect
two
plate
time
ad
ml
dna
mixtur
tube
ml
hb
mix
incub
min
room
temperatur
allow
precipit
form
add
ml
media
tube
mix
total
volum
tube
ml
pipett
ml
onto
two
plate
repeat
remaind
plate
incub
h
centrifug
g
min
pellet
cell
discard
media
resuspend
pellet
pb
wash
pellet
centrifug
g
min
discard
pb
freez
pellet
frozen
pellet
store
process
later
time
adjust
ph
n
naoh
bring
final
volum
l
dh
steril
filter
store
aliquot
note
optim
ph
rang
hb
ph
hb
key
factor
influenc
precipit
format
resuspend
pellet
ml
lysi
buffer
lyse
cell
three
freezethaw
cycl
thaw
pellet
water
bath
freez
cell
etohdri
ice
bath
repeat
twice
transfer
lysat
dounc
homogen
homogen
lysat
stroke
shear
cellular
dna
ml
lysat
add
g
cscl
homogen
cscl
dissolv
complet
fill
six
ml
ultra
clear
ultracentrifug
tube
beckman
ml
lysat
underlay
ml
cscl
gml
balanc
tube
use
cscl
gml
prior
ultracentrifug
centrifug
h
g
rpm
sw
rotor
collect
aav
gradient
drip
fraction
verifi
densiti
fraction
refractometri
densiti
infecti
aav
virion
gcm
empti
aav
particl
di
particl
densiti
gcm
dialyz
aavcontain
fraction
buffer
use
column
chromatographi
td
buffer
heparin
column
mm
nacl
mm
tri
ph
q
sepharos
purif
purifi
use
either
heparin
affin
chromatographi
ionexchang
q
sepharos
chromatographi
use
column
plate
describ
step
aav
purif
heparin
chromatographi
aav
purif
q
sepharos
chromatographi
purif
method
describ
zolotukhin
et
al
lysi
buffer
prepar
l
mm
nacl
stock
gmol
g
mm
tri
stock
gmol
g
adjust
ph
hcl
bring
final
volum
l
dh
filter
steril
store
room
temperatur
gml
cscl
pb
dissolv
g
cscl
pb
adjust
final
volum
ml
weigh
ml
verifi
densiti
gml
filter
steril
store
room
temperatur
gml
cscl
pb
dissolv
g
cscl
pb
adjust
final
volum
ml
weigh
ml
verifi
densiti
gml
filter
steril
store
room
temperatur
td
buffer
prepar
l
pb
ml
pb
invitrogen
collect
iodixanol
band
interfac
band
done
set
ring
stand
place
tube
clamp
swab
top
bottom
tube
alcohol
swab
vent
top
tube
needl
collect
fraction
bottom
tube
dialyz
viruscontain
fraction
buffer
use
column
chromatographi
td
buffer
heparin
column
mm
nacl
mm
tri
ph
q
sepharos
purif
purifi
use
either
heparin
affin
chromatographi
ionexchang
q
sepharos
chromatographi
use
column
plate
describ
step
aav
purif
heparin
chromatographi
aav
purif
q
sepharos
chromatographi
purif
method
describ
zolotukhin
et
al
reequilibr
column
wash
ten
column
volum
td
appli
dialyz
viru
either
cesium
gradient
iodixanol
gradient
column
wash
column
ten
volum
td
elut
five
column
volum
elut
buffer
use
either
continu
step
gradient
elut
nacl
collect
fraction
dialyz
viru
prepar
storag
buffer
suitabl
formul
freez
resuspend
cell
pellet
one
cell
factori
ml
largescal
lysi
buffer
mm
triscl
mm
nacl
deoxychol
benzonas
uml
deoxychol
use
lysi
buffer
reduc
aggreg
ten
cell
factori
lyse
cell
singlepass
use
microfluid
microfluid
form
fine
suspens
load
onto
column
load
lysat
onto
streamlin
heparin
column
pharmacia
flow
rate
mlmin
use
aktafplc
pharmacia
wash
column
four
column
volum
lysi
buffer
follow
five
column
volum
pb
elut
viru
pb
contain
nacl
total
ionic
strength
monitor
absorb
peak
fraction
ml
bring
nacl
concentr
peak
fraction
nacl
load
onto
phenyl
sepharos
column
ml
column
pharmacia
hydrophob
interact
column
flowthrough
contain
viru
collect
flowthrough
dilut
mm
nacl
steril
water
viru
load
onto
ml
sp
sepharos
column
pharmacia
flow
rate
mlmin
wash
column
ten
column
volum
pb
elut
viru
pb
contain
nacl
mm
total
ionic
strength
monitor
absorb
aliquot
store
dialyz
viru
prep
storag
buffer
mm
triscl
mm
nacl
ph
aliquot
freez
dialyz
aav
vector
proteas
digest
reaction
buffer
mm
triscl
mm
nacl
ph
need
digest
capsid
either
final
concentr
trypsin
proteinas
k
reaction
h
serotyp
undigest
sampl
includ
control
proteas
commerci
avail
sigma
add
equal
volum
laemmli
sampl
buffer
contain
sodium
dodecyl
sulfat
sd
mm
boil
sampl
min
separ
proteolyt
fragment
sdspage
gel
min
v
constant
voltag
dye
front
reach
bottom
gel
transfer
protein
nitrocellulos
western
blot
transfer
buffer
mm
tri
mm
glycin
wv
sd
methanol
h
constant
amper
probe
membran
rabbit
polyclon
antisera
aav
capsid
duplic
sampl
run
probe
aav
antibodi
determin
origin
fragment
produc
exampl
signal
monoclon
antibodi
demonstr
fragment
common
ctermin
end
altern
probe
monoclon
antibodi
signal
western
blot
would
demonstr
origin
fragment
uniqu
nterminu
epitop
conserv
among
aav
serotyp
polyclon
antibodi
develop
aav
serotyp
antiaav
capsid
antibodi
avail
progen
american
research
product
inc
